What is Anktiva studying for Long COVID?

Anktiva is being studied to understand its safety and how it may affect persistent symptoms in people with Long COVID. This Phase 2 clinical trial by ImmunityBio, Inc. aims to evaluate if Anktiva can help improve quality of life for patients who continue to experience symptoms after COVID-19 infection.

Who may be eligible for this Long COVID clinical trial?

Adults aged 18 to 70 with confirmed prior COVID-19 infection and ongoing symptoms of Long COVID may be eligible. Participants must not be hospitalized and should be in generally stable health without certain infections or autoimmune diseases. Please review eligibility criteria for more details.

Is there any cost to participate in this Long COVID clinical trial?

Study-related care, including the study drug and all trial visits, is provided at no cost. However, personal travel expenses to attend study appointments may vary and are not guaranteed to be covered.

Actively Recruiting

Phase 2

Age: 18Years - 70Years

All Genders

ID07123727

Evaluation of Nogapendekin Alfa Inbakicept NAI for Safety in Adults With Long COVID

Led by ImmunityBio, Inc. · Updated on 2026-05-13

Participants Needed

Research Sites

N/A

Total Duration

AI-Summary

What this Trial Is About

Researchers are studying the safety and effectiveness of Anktiva, also known as Nogapendekin Alfa Inbakicept NAI, in people experiencing Long COVID, which means continuing symptoms after a COVID-19 infection has ended. This Phase 2 study aims to understand how this treatment may help patients with persistent symptoms that affect their quality of life. The study is sponsored by ImmunityBio, Inc. and focuses on adults aged 18 to 70 years with confirmed Long COVID symptoms lasting at least 60 days. Participants will receive 600 micrograms of Anktiva administered by a subcutaneous injection. The study is a single-arm trial, meaning all participants receive this treatment without comparison to a placebo or other drug. Treatment and monitoring will occur over approximately 75 days, including the time after the final dose to track safety and response. There are no placebo groups or blinding in this research. During the study, participants will attend visits for assessments including blood tests, vital signs monitoring temperature, heart rate, blood pressure, respiratory rate, oxygen saturation, and symptom evaluations. Researchers will monitor for any treatment-related side effects or serious adverse events up to 30 days after the last dose. They will also assess changes in lymphocyte counts and other laboratory values. Participants should expect regular study visits and evaluations for safety and effectiveness over the treatment period.

CONDITIONS

Brief Title

A Study to Examine Anktiva for the Treatment of COVID-19.

Who Can Participate

Age: 18Years - 70Years

All Genders

Eligibility Criteria

You may qualify if you...

Age 18 years or older and under 70 years
History of at least one confirmed SARS-CoV-2 infection by positive NAAT or antigen test
Clinical evidence of Long COVID confirmed by investigator assessment
At least 2 new or worsened symptoms since COVID-19 infection that impact quality of life
Symptoms present for at least 60 days before screening
At least 90 days have passed since most recent COVID-19 infection
Not currently hospitalized
Body mass index (BMI) between 18 and 50 kg/m2
Stable health within 28 days before screening
For males with partners who can become pregnant, agreement to use contraception and inform partners
For females who engage in intercourse with males, not pregnant or breastfeeding and agreement to contraceptive conditions
Willingness and ability to comply with study visits and protocol
Written informed consent obtained

You will not qualify if you...

Received SARS-CoV-2 antiviral or monoclonal antibody within 30 days before first dose or plans to receive before study exit
Plans to receive any SARS-CoV-2 vaccine or booster within 14 days before first dose or before study exit
History of autoimmune diseases such as celiac disease, rheumatoid arthritis, psoriasis, or inflammatory bowel diseases
Active cardiovascular disease including recent heart attack, bypass surgery, heart failure with reduced ejection fraction, or pulmonary hypertension
Known stroke within 3 months prior to first dose
Active bacterial, fungal, viral, or other infection needing treatment within 14 days before first dose
Major surgery within 3 months before first dose or planned during first 75 days of study
Unplanned hospitalization for more than 24 hours within 28 days before screening
Active or prior Hepatitis B infection
Active Hepatitis C infection (cured Hep C allowed)
Laboratory abnormalities such as low white blood cell or platelet counts, low hemoglobin, elevated liver enzymes, or low kidney function
Known or suspected HIV infection
End stage kidney disease requiring dialysis
Diabetes requiring systemic medication or insulin
Severe liver impairment
Moderate or severe immunocompromise including recent cancer treatment or organ transplant
Prior diagnosis of myalgic encephalomyelitis/chronic fatigue syndrome or dysautonomia unrelated to COVID-19
Allergy to any study drug components or history of severe allergic reactions
Participation in another investigational product trial within 28 days before first dose
Current alcohol or illicit drug use that precludes participation
Any condition that investigator believes would compromise safety or data quality

Research Team

Kayleigh Russell

Jayson Garmizo

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here

Evaluation of Nogapendekin Alfa Inbakicept NAI for Safety in Adults With Long COVID

On this page

AI-Summary

What this Trial Is About

Brief Title

Who Can Participate

Eligibility Criteria

Research Team

Not the Right Trial for You?

On this page

Who Can Participate

Eligibility Criteria